Immunotherapy
Risks associated with use of intravenous immunoglobulin reviewed
Published in Blood Weekly, December 18th, 2003
According to published research from the United States, "Although U.S. immune globulin intravenous (human) (IGIV) products have been regarded as safe, it is important to recognize that many of the controlled clinical studies of IGIVs have been of modest size and have limited power to define the incidence of only the most common adverse events (AEs). A significant number of 'postmarketing' serious AEs affecting renal, cardiovascular, CNS, integumentary, and hematologic organ systems have been reported."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2003-12-18)
More Articles from Blood Weekly
- Pediatric Hemodialysis
Novel pre-dialysis treatment normalizes blood prime pH and electrolyte levels - Stem-Cell Research
Culture system for growth of c-Kit(-) hematopoietic cells developed - Critical Care Medicine
Organizational approach more effective than education in reducing diagnostic blood loss - Immunology
Innate immune system fully functional in neonates - Leukemia Animal Models
Murine model of megakaryocytic myeloproliferative syndrome developed - Stem-Cell Research
Thrombopoietin stimulates Hoxb4 expression by primitive hematopoietic cells - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
